Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts
- PMID: 8838504
Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts
Abstract
Objective: To investigate the effects of tenidap, a new antirheumatic drug, sodium diclofenac, a non-steroidal antiinflammatory drug, and a disease modifying antirheumatic drug, hydroxychloroquine, on the level and expression of interleukin 1 receptors (IL-1R) on synovial fibroblasts from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). In addition, the effect of tenidap on IL-1 stimulated collagenase gene expression was studied.
Methods: Binding assays were performed using [125I]-IL-1 beta as radioligand. Flow cytometry was done using a specific antibody against type I IL-1R. Protein synthesis was determined by [3H]-leucine incorporation. Levels of expression were determined by Northern Blot for collagenase and by reverse transcription polymerase chain reaction (RT-PCR) for type I IL-1R.
Results: Tenidap produced for both OA and RA synovial fibroblasts a dose dependent decrease in the number of IL-1 binding sites/cell. A reduction of 41% (2.5 micrograms/ml) to 81% (at therapeutic concentration, 20 micrograms/ml) was noted for OA, while 29% (2.5 micrograms/ml) to 89% (20 micrograms/ml) was found for RA cells. Diclofenac produced no effect on OA cells, and minimal inhibition of RA synovial fibroblasts was observed only at pharmacological concentration (12%, 300 mg/ml). Hydroxychloroquine had effects similar to diclofenac. The decreased number of IL-1 binding sites/cell by tenidap was time dependent and reached 93% inhibition after 48 h. The effect of tenidap appears to be posttranscriptional, judged by the marked reduction of the type I IL-1R protein/cell and the absence of effect on its mRNA level. Tenidap also markedly reduced the IL-1 induced collagenase expression in synovial fibroblasts.
Conclusion: At therapeutic concentrations tenidap is a potent inhibitor of type I IL-1R in OA and RA synovial fibroblasts. The effect of tenidap was considerably more marked than diclofenac or hydroxychloroquine.
Similar articles
-
In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis.J Rheumatol. 1996 Jan;23(1):16-23. J Rheumatol. 1996. PMID: 8838503
-
The effects of tenidap on canine experimental osteoarthritis: II. Study of the expression of collagenase-1 and interleukin 1beta by in situ hybridization.J Rheumatol. 1998 May;25(5):951-8. J Rheumatol. 1998. PMID: 9598897
-
Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor.Lab Invest. 1995 Sep;73(3):347-55. Lab Invest. 1995. PMID: 7564267
-
Tenidap--a new antiarthritic agent.Agents Actions Suppl. 1993;44:161-3. Agents Actions Suppl. 1993. PMID: 8372726 Review.
-
[Importance of interleukin-I receptors in osteoarthritis].Rev Rhum Ed Fr. 1994 Nov 15;61(9 Pt 2):109S-113S. Rev Rhum Ed Fr. 1994. PMID: 7858606 Review. French.
Cited by
-
The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders.Drugs Aging. 2001;18(2):87-99. doi: 10.2165/00002512-200118020-00002. Drugs Aging. 2001. PMID: 11346130 Review.
-
Esculetin inhibits cartilage resorption induced by interleukin 1alpha in combination with oncostatin M.Ann Rheum Dis. 2001 Feb;60(2):158-65. doi: 10.1136/ard.60.2.158. Ann Rheum Dis. 2001. PMID: 11156550 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical